First-line Enfortumab Vedotin Plus Pembrolizumab in Platinum-ineligible Advanced Urothelial Carcinoma. (PubMed, Cancer Diagn Progn) - Sep 3, 2026 - "First-line enfortumab vedotin plus pembrolizumab showed encouraging clinical activity and acceptable tolerability in selected platinum-ineligible patients with advanced urothelial carcinoma. Given the small subgroup size, these findings should be interpreted as descriptive and hypothesis-generating."
Journal • Oncology • Solid Tumor • Urothelial Cancer
|
|
Daisuke Igarashi; G O Kaneko; Suguru Shirotake
|